Incyte To Present Late-Breaking Phase 3 Results For Retifanlimab And Initial Data From Phase 1 CDK2 Inhibitor Program At The ESMO Congress 2024
Incyte To Present Late-Breaking Phase 3 Results For Retifanlimab And Initial Data From Phase 1 CDK2 Inhibitor Program At The ESMO Congress 2024
Incyte (NASDAQ:INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2024, to be held September 13-17 in Barcelona and virtually.- Presidential Symposium to feature Phase 3 retifanlimab (Zynyz) results in squamous cell anal carcinoma (SCAC); filing of supplemental Biologics License Application (sBLA) in SCAC planned by year end 2024
- 总统研讨会将展示第 3 期雷替凡利单抗（Zynyz）在鳞状细胞肛癌（SCAC）中的结果；计划于 2024 年年底申请补充生物制品许可申请（sBLA）在SCAC中的使用。
- Mini oral presentation to highlight initial Phase 1 data from potential first-in-class CDK2 inhibitor program in patients with CCNE1 ovarian and other advanced cancers
- 迷你口头报告将重点介绍潜在首例 CDK2 抑制剂项目在患有 CCNE1 卵巢癌和其他晚期癌症患者中的初步 1 期数据。
- Incyte to host an in-person analyst and investor event to review key data at ESMO, including new results from a later CDK2 data cut-off, on Saturday, September 14, 2024, from 1:00-2:30 p.m. ET (7:00-8:30 p.m. CEST)
- 因塞特将举办一次面对面的分析师和投资者活动，审查ESMO的关键数据，包括来自后续 CDK2 数据截止日的新结果，时间为 2024 年 9 月 14 日，下午 1:00-2:30 美国东部时间（晚上 7:00-8:30 中欧时间）。
Incyte (NASDAQ:INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2024, to be held September 13-17 in Barcelona and virtually.
因塞特（纳斯达克：INCY）今日宣布，公司将在即将举行的 2024 年欧洲医学肿瘤学会（ESMO）大会上，展示其肿瘤学组合中的关键数据，大会将于 9 月 13-17 日在巴塞罗那举行，并提供虚拟会议。
